Issue 4/2017

Antioxidant potential of essential oil from Lavandula angustifolia in in vitro and ex vivo cultured liver cells (485 — 493)

K. KOZICS, A. SRANCIKOVA, E. SEDLACKOVA, E. HORVATHOVA, M. MELUSOVA, V. MELUS, Z. KRAJCOVICOVA, M. SRAMKOVA

DOI: 10.4149/neo_2017_401

Identification of prognostic risk factors of acute lymphoblastic leukemia based on mRNA expression profiling (494 — 501)

C. LI, L. KUANG, B. ZHU, J. CHEN, X. WANG, X. HUANG

DOI: 10.4149/neo_2017_402

NFAT5 inhibits invasion and promotes apoptosis in hepatocellular carcinoma associated with osmolality (502 — 510)

X. QIN, Y. WANG, J. LI, Y. XIAO, Z. LIU

DOI: 10.4149/neo_2017_403

The Effects of Lentivirus-mediated shRNA Interference Targeting Mcl-1 on Growth of NK/T-cell Lymphoma (511 — 517)

X. ZHANG, C. SHI, G. YUE, H. GUO, X. FU, X. LI, L. LI, X. WANG, Z. LI, Y. CHANG, M. ZHANG, Q. CHEN

DOI: 10.4149/neo_2017_404

Saikosaponin-d suppresses cell growth in renal cell carcinoma through EGFR/p38 signaling pathway (518 — 525)

C. CAI, H. ZHANG, Y. OU, Y. JIANG, D. ZHONG, H. QI, Q. DANG

DOI: 10.4149/neo_2017_405

miR-361-5p suppresses lung cancer cell lines progression by targeting FOXM1 (526 — 534)

X. W. HOU, X. SUN, Y. YU, H. M. ZHAO, Z. J. YANG, X. WANG, X. C. CAO

DOI: 10.4149/neo_2017_406

FBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1α (535 — 542)

L. SHI, C. HE, Z. LI, Z. WANG, Q. ZHANG

DOI: 10.4149/neo_2017_407

MiR-34a suppresses HNSCC growth through modulating cell cycle arrest and senescence (543 — 553)

Y. WANG, J. CHEN, X. CHEN, F. JIANG, Y. SUN, Y. PAN, W. ZHANG, J. ZHANG

DOI: 10.4149/neo_2017_408

MicroRNA-300 targets hypoxia inducible factor-3 alpha to inhibit tumorigenesis of human non-small cell lung cancer (554 — 562)

Y. ZHANG, Y. GUO, C. YANG, S. ZHANG, X. ZHU, L. CAO, W. NIE, H. YU

DOI: 10.4149/neo_2017_409

Epigallocatechin gallate inhibits the growth of salivary adenoid cystic carcinoma cells via the EGFR/Erk signal transduction pathway and the mitochondria apoptosis pathway (563 — 570)

L. X. WENG, G. H. WANG, H. YAO, M. F. YU, J. LIN

DOI: 10.4149/neo_2017_410

Microarray profiling defines circulating microRNAs associated with myelodysplastic syndromes (571 — 578)

M. DOSTALOVA MERKEROVA, A. HRUSTINCOVA, Z. KREJCIK, H. VOTAVOVA, E. RATAJOVA, J. CERMAK, M. BELICKOVA

DOI: 10.4149/neo_2017_411

miR-215 promotes cell migration and invasion of gastric cancer cell lines by targeting FOXO1 (579 — 587)

Y. ZANG, T. WANG, J. PAN, F. GAO

DOI: 10.4149/neo_2017_412

Prognostic significance of the tumor-stroma ratio in gallbladder cancer (588 — 593)

H. LI, S. L. YUAN, Z. Z. HAN, J. HUANG, L. CUI, C. Q. JIANG, Y. ZHANG

DOI: 10.4149/neo_2017_413

Preoperative mean platelet volume and platelet distribution associated with thyroid cancer (594 — 598)

Y. J. YU, N. LI, Z. Y. YUN, Y. NIU, J. J. XU, Z. P. LIU, T. LIU, R. T. WANG, K. J. YU

DOI: 10.4149/neo_2017_414

Ultrahypofractionated CyberKnifeTM based stereotactic radiotherapy versus conventional radiotherapy in patients with prostate cancer – acute toxicity evaluation in two phase II prospective studies (599 — 604)

G. GŁOWACKI, W. MAJEWSKI, P. WOJCIESZEK, K. GRABINSKA, G. WOZNIAK, L. MISZCZYK

DOI: 10.4149/neo_2017_421

Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed (605 — 610)

O. FIALA, P. HOSEK, M. PESEK, J. FINEK, J. RACEK, T. BUCHLER, A. POPRACH, K. HEJDUK, R. CHLOUPKOVA, O. SOREJS, M. ECKSTEINOVA, M. VITOVEC, K. CIZKOVA, R. KUCERA, O. TOPOLCAN

DOI: 10.4149/neo_2017_416

Plasma cell-free DNA integrity plus circulating tumor cells: a potential biomarker of no distant metastasis breast cancer (611 — 618)

W. WANG, M. LIANG, G. MA, L. LI, W. ZHOU, T. XIA, H. XIE, S. WANG

DOI: 10.4149/neo_2017_417

Correlation between circulating tumor cells EGFR expression and T cell subsets in advanced non-small cell lung cancer patients after tyrosine kinase inhibitor treatment (619 — 625)

C. TU, Y. ZHU, B. JIANG, W. HE, C. JIN

DOI: 10.4149/neo_2017_418

BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma (626 — 632)

X. BAI, L. L. MAO, Z. H. CHI, X. N. SHENG, C. L. CUI, Y. KONG, J. DAI, X. WANG, S. M. LI, B. X. TANG, B. LIAN, L. ZHOU, X. Q. YAN, J. GUO, L. SI

DOI: 10.4149/neo_2017_419

High Farnesoid X Receptor (FXR) expression is a strong and independent prognosticator in invasive breast carcinoma (633 — 639)

C. GIAGINIS, D. KARANDREA, P. ALEXANDROU, I. GIANNOPOULOU, G. TSOUROUFLIS, C. TROUNGOS, E. DANAS, A. KERAMOPOULOS, E. PATSOURIS, L. NAKOPOULOU, S. THEOCHARIS

DOI: 10.4149/neo_2017_420